ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Streamline Health® Reports Second Quarter 2021 Financial Results

September 8, 2021 GMT

Second quarter 2021 Revenues of $2.9 million; ($0.1 million) Net Loss; ($0.8 million) Adjusted EBITDA

Atlanta, GA , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM) (“Streamline”), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced financial results for the second quarter of fiscal year 2021, which ended July 31, 2021.

Total revenues for the second quarter of fiscal 2021 were $2.9 million, consistent with the prior year period. SaaS revenue grew approximately 59%, compared to the same quarter a year ago. The consistent revenue volume during the quarter was the result of higher revenue from SaaS offset by lower revenue from professional services, software licenses and maintenance and support. Recurring revenue comprised 84% of second quarter fiscal 2021 revenue compared to 71% of second quarter fiscal 2020 revenue.

ADVERTISEMENT

Net loss for the second quarter of fiscal 2021 was ($0.1 million) as compared to a net loss of ($1.1 million) during the second quarter of fiscal 2020. Second quarter fiscal 2021 net loss included $11,000 of income from discontinued operations of the Company’s legacy ECM business, the sale of which closed on February 24, 2020, compared to $28,000 of income from discontinued operations during the second quarter of fiscal 2020. Income from discontinued operations was offset by a loss from continuing operations for the three months ended July 31, 2021 and 2020 of ($0.1 million) and ($1.2 million), respectively. Loss from continuing operations for the three months ended July 31, 2021 included $2.3 million of income associated with loan forgiveness.

Adjusted EBITDA for the second quarter of fiscal 2021 was a loss of ($0.8 million), compared to an adjusted EBITDA loss of ($0.4 million) in the second quarter of fiscal 2020.

“As a result of our team’s execution to restructure and position Streamline for growth, we were thrilled to enter a new chapter with our recent acquisition of Avelead. Thanks to our focus on improved sales and customer success, we are ready to capitalize on our tremendous market opportunity while maintaining strong relationships with our existing customers.” stated Tee Green, President and Chief Executive Officer, Streamline.

“We believe that the Delta variant of COVID has delayed our reporting of successes on the sales side, however, it has not deterred our improving the systems and processes that enable the growth we are expecting. Today, we are more capable than ever of supporting our healthcare provider customers through pre-bill revenue cycle solutions to ensure their revenue integrity and improved financial performance.”

Highlights from the second quarter ended July 31, 2021 included:

ADVERTISEMENT
 Revenue for the second quarter of fiscal 2021 was $2.9 million; SaaS revenue grew 11%, sequentially, compared to the first quarter of fiscal 2021;
 Loss from continuing operations for the second quarter of fiscal 2021 was ($0.1 million);
 Adjusted EBITDA for the second quarter of fiscal 2021 was ($0.8 million);
 Total bookings (total contract value) for the second quarter of fiscal 2021 were $1.6 million.

Conference Call

The Company will conduct a conference call to review the results and to provide additional detail about its recent acquisition on Thursday, September 9, 2021 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.

A replay of the conference call will be available from Thursday September 9, 2021 at 12:00 PM ET to Thursday, September 16, 2021 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13722259. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

Non-GAAP Financial Measures

Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.

Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure is included in this press release.

About Streamline

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.
  
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of backlog, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
Jacob.goldberger@streamlinehealth.net
  

STREAMLINE HEALTH SOLUTIONS, INC.
CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

  Three Months Ended  Six Months Ended 
  July 31,  July 31, 
  2021  2020  2021  2020 
Revenues:                
Software licenses $-  $215,000  $135,000  $215,000 
Professional services  30,000   160,000   108,000   312,000 
Audit Services  443,000   463,000   947,000   1,007,000 
Maintenance and support  1,087,000   1,228,000   2,144,000   2,486,000 
Software as a service  1,308,000   821,000   2,485,000   1,711,000 
Total revenues  2,868,000   2,887,000   5,819,000   5,731,000 
                 
Operating expenses:                
Cost of software licenses  143,000   125,000   279,000   202,000 
Cost of professional services  261,000   269,000   475,000   510,000 
Cost of audit services  376,000   373,000   765,000   733,000 
Cost of maintenance and support  80,000   182,000   166,000   368,000 
Cost of software as a service  578,000   403,000   1,188,000   808,000 
Selling, general and administrative  2,515,000   2,284,000   5,068,000   4,576,000 
Research and development  964,000   509,000   1,941,000   1,193,000 
Non-routine costs  336,000   -   777,000   - 
Loss on exit of membership agreement  -   -   -   105,000 
Total operating expenses  5,253,000   4,145,000   10,659,000   8,495,000 
Operating loss  (2,385,000)  (1,258,000)  (4,840,000)  (2,764,000)
Other (expense) income:                
Interest expense  (9,000)  (13,000)  (22,000)  (27,000)
Miscellaneous expense  (8,000)  (64,000)  6,000   (82,000)
Forgiveness of PPP loan and accrued interest  2,327,000   -   2,327,000   - 
Loss before income taxes  (75,000)  (1,335,000)  (2,529,000)  (2,873,000)
Income tax benefit (expense)  4,000   172,000   (5,000)  733,000 
Loss from continuing operations $(71,000) $(1,163,000) $(2,534,000) $(2,140,000)
Income from discontinued operations:                
Gain on sale of discontinued operations  -   4,000   -   6,013,000 
Income from discontinued operations  11,000   104,000   332,000   241,000 
Income tax expense  -   (80,000)  -   (1,576,000)
Income from discontinued operations  11,000   28,000   332,000   4,678,000 
Net (loss) income $(60,000) $(1,135,000) $(2,202,000) $2,538,000 
                 
Basic Earnings per Share:                
Continuing operations $(0.00) $(0.04) $(0.06) $(0.07)
Discontinued operations  0.00   0.00   0.01   0.16 
Net (loss) income $(0.00) $(0.04) $(0.05) $0.09 
Weighted average number of common shares - basic  41,288,709   30,026,658   39,393,333   29,897,236 
                 
Diluted Earnings per Share:                
Continuing operations $(0.00) $(0.04) $(0.06) $(0.07)
Discontinued operations  0.00   0.00   0.01   0.15 
Net (loss) income $(0.00) $(0.04) $(0.05) $0.08 
Weighted average number of common shares – diluted  41,737,231   30,421,473   39,960,998   30,229,595 

STREAMLINE HEALTH SOLUTIONS, INC.
CONSOLIDATED AND CONDENSED BALANCE SHEETS
(Unaudited)

  July 31,  January 31, 
  2021  2021 
Assets        
Current assets:        
Cash and cash equivalents $15,847,000  $2,409,000 
Accounts receivable, net  2,625,000   2,929,000 
Contract receivables  236,000   174,000 
Prepaid and other current assets  788,000   1,216,000 
Current assets from discontinued operations  181,000   587,000 
Total current assets  19,677,000   7,315,000 
         
Non-current assets:        
Property and equipment, net  76,000   104,000 
Right of use asset on operating lease  306,000   391,000 
Capitalized software development costs, net  5,667,000   5,945,000 
Intangible assets, net  393,000   624,000 
Goodwill  10,712,000   10,712,000 
Other non-current assets  1,003,000   873,000 
Long-term assets from discontinued operations  3,000   13,000 
Total non-current assets  18,160,000   18,662,000 
  $37,837,000  $25,977,000 
         
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable $363,000  $272,000 
Accrued expenses  1,324,000   908,000 
Current portion of term loan  -   1,534,000 
Deferred revenues  4,474,000   3,862,000 
Current portion of operating lease obligation  201,000   198,000 
Current liabilities from discontinued operations  283,000   595,000 
Total current liabilities  6,645,000   7,369,000 
         
Non-current liabilities:        
Term loan, net of current portion  -   767,000 
Deferred revenues, less current portion  163,000   130,000 
Operating Lease obligations, less current portion  129,000   222,000 
Total non-current liabilities  292,000   1,119,000 
Total liabilities  6,937,000   8,488,000 
         
Stockholders’ equity  30,900,000   17,489,000 
  $37,837,000  $25,977,000 

STREAMLINE HEALTH SOLUTIONS, INC.
CONSOLIDATED AND CONDENSED STATEMENT OF CASH FLOWS
(Unaudited)

  Six Months Ended 
  July 31, 
  2021  2020 
Cash flows from continuing operating activities:        
Loss from continuing operations $(2,534,000) $(2,140,000)
Depreciation  37,000   31,000 
Amortization of capitalized software development costs  984,000   651,000 
Amortization of intangible assets  231,000   247,000 
Amortization of other deferred costs  242,000   153,000 
Valuation adjustments  -   31,000 
Loss on exit of membership agreement  -   105,000 
Share-based compensation expense  1,122,000   575,000 
Benefit for accounts receivable allowance  (1,000)  (15,000)
Forgiveness of PPP Loan and accrued interest  (2,327,000)  - 
Benefit for income taxes  -   (733,000)
Changes in assets and liabilities  709,000   (876,000)
         
Net cash used in operating activities  (1,537,000)  (1,971,000)
         
Net cash from operating activities - discontinued operations  436,000   (2,374,000)
         
Cash flows used in investing activities:        
Capitalization of software development costs  (706,000)  (1,094,000)
Purchases of property and equipment  (3,000)  (34,000)
Proceeds from sale of ECM assets  800,000   11,288,000 
Net cash provided by investing activities  91,000   10,160,000 
         
Cash flows from financing activities:        
Proceeds from issuance of common stock  16,100,000   - 
Payments for costs directly attributable to the issuance of common stock  (1,318,000)  - 
Proceeds from term loan  -   2,301,000 
Principal payments on term loan  -   (4,000,000)
Other  (334,000)  (58,000)
Net cash provided by (used in) financing activities  14,448,000   (1,757,000)
Net increase in cash and cash equivalents  13,438,000   4,058,000 
Cash and cash equivalents at beginning of period  2,409,000   1,649,000 
Cash and cash equivalents at end of period $15,847,000  $5,707,000 

STREAMLINE HEALTH SOLUTIONS, INC.
New Bookings
(Unaudited)

  July 31, 2021 
   Three Months
Ended
   Six Months
Ended
 
Software licenses $-   135,000 
Professional Services  149,950   348,950 
Audit Services  21,800   407,800 
Maintenance and Support  -   135,000 
Software as a Service  1,455,000   3,180,000 
Q2 2021 Bookings $1,626,750  $4,206,750 
Q2 2020 Bookings $2,865,000  $4,150,000 

STREAMLINE HEALTH SOLUTIONS, INC.
Reconciliation of loss from continuing operations to non-GAAP Adjusted EBITDA
(in thousands)
(Unaudited)

  Three Months Ended July 31,  Six Months Ended July 31, 
  2021  2020  2021  2020 
Loss from continuing operations $(71) $(1,163) $(2,534) $(2,140)
Interest expense  9   13   22   27 
Income tax (benefit) expense  (4)  (172)  5   (733)
Depreciation  16   17   37   31 
Amortization of capitalized software development costs  478   362   984   651 
Amortization of intangible assets  116   124   231   247 
Amortization of other costs  126   78   242   153 
EBITDA  670   (741)  (1,013)  (1,764)
Share-based compensation expense  557   349   1,122   613 
Non-cash valuation adjustments  -   14   -   31 
Loss on exit of operating lease  -   -   -   105 
Other non-recurring operating expenses  336   -   793   - 
Forgiveness of PPP Loan and accrued interest  (2,327)  -   (2,327)  - 
Adjusted EBITDA $(764) $(378) $(1,425) $(1,015)
Adjusted EBITDA per diluted share:                
Net loss per common share – diluted $(0.00) $(0.04) $(0.05) $0.08 
Adjusted EBITDA per adjusted diluted share $(0.02) $(0.01) $(0.04) $(0.03)
                 
Diluted weighted average shares  41,288,709   30,026,658   39,393,333   29,897,236 
Includable incremental shares — Adjusted EBITDA  448,522   394,815   567,665   332,359 
Adjusted diluted shares  41,737,231   30,421,473   39,960,998   30,229,595